CD137 stimulation enhances cetuximab-induced natural killer: dendritic cell priming of antitumor T-cell immunity in patients with head and neck cancer

RM Srivastava, S Trivedi, F Concha-Benavente… - Clinical Cancer …, 2017 - AACR
RM Srivastava, S Trivedi, F Concha-Benavente, SP Gibson, C Reeder, S Ferrone, RL Ferris
Clinical Cancer Research, 2017AACR
Purpose: Cetuximab, an EGFR-specific antibody (mAb), modestly improves clinical outcome
in patients with head and neck cancer (HNC). Cetuximab mediates natural killer (NK) cell:
dendritic cell (DC) cross-talk by cross-linking FcγRIIIa, which is important for inducing
antitumor cellular immunity. Cetuximab-activated NK cells upregulate the costimulatory
receptor CD137 (4-1BB), which, when triggered by agonistic mAb urelumab, might enhance
NK-cell functions, to promote T-cell–based immunity. Experimental design: CD137 …
Abstract
Purpose: Cetuximab, an EGFR-specific antibody (mAb), modestly improves clinical outcome in patients with head and neck cancer (HNC). Cetuximab mediates natural killer (NK) cell:dendritic cell (DC) cross-talk by cross-linking FcγRIIIa, which is important for inducing antitumor cellular immunity. Cetuximab-activated NK cells upregulate the costimulatory receptor CD137 (4-1BB), which, when triggered by agonistic mAb urelumab, might enhance NK-cell functions, to promote T-cell–based immunity.
Experimental design: CD137 expression on tumor-infiltrating lymphocytes was evaluated in a prospective cetuximab neoadjuvant trial, and CD137 stimulation was evaluated in a phase Ib trial, in combining agonistic urelumab with cetuximab. Flow cytometry and cytokine release assays using NK cells and DC were used in vitro, testing the addition of urelumab to cetuximab-activated NK, DC, and cross presentation to T cells.
Results: CD137 agonist mAb urelumab enhanced cetuximab-activated NK-cell survival, DC maturation, and tumor antigen cross-presentation. Urelumab boosted DC maturation markers, CD86 and HLA DR, and antigen-processing machinery (APM) components TAP1/2, leading to increased tumor antigen cross-presentation. In neoadjuvant cetuximab-treated patients with HNC, upregulation of CD137 by intratumoral, cetuximab-activated NK cells correlated with FcγRIIIa V/F polymorphism and predicted clinical response. Moreover, immune biomarker modulation was observed in an open label, phase Ib clinical trial, of patients with HNC treated with cetuximab plus urelumab.
Conclusions: These results suggest a beneficial effect of combination immunotherapy using cetuximab and CD137 agonist in HNC. Clin Cancer Res; 23(3); 707–16. ©2016 AACR.
AACR